The Oxford Tropical Network (OTN) Conference 2025 took place this year in the vibrant coastal city of Mombasa, Kenya, bringing together a diverse community of researchers and scientists from across ...
The article looks at how participatory visual methods such as community mapping, drawing, photography, or video can help communities express their own understanding of hazards like floods or storms, vulnerabilities, ...
Recently, a series of mass drug administration (MDA) studies have been conducted in West Africa to assess their impact on malaria transmission using ivermectin. Ivermectin is a potent endectocide with demonstrated ...
In 2022, Uganda reported an alarming outbreak of Marburg virus disease (MARV). Two people in the southwest developed high fever, vomiting, and bleeding, which are classic signs of MARV, one ...
Antimicrobial resistance (AMR) is a growing threat in Cambodia, where it is estimated that since 1990 approximately 3,000 lives have been lost each year as a result of drug-resistant infections. ...
On Sept 8, 2025, West African Ministers of Health pledged their joint commitment to advance development of, and readiness for, much-needed vaccines against Lassa fever in recognition of the significant regional health security threat posed by the disease Read more
CEPI has announced a funding opportunity to develop innovative analytical technologies for vaccines. The goal is to reduce vaccine development, manufacturing, and release times; lower costs, improve equitable deployment in Low to Middle-Income Countries, and enhance analytical insights for vaccines. Read more
Developed from a systematic review of peer-reviewed studies, this platform allows users to explore findings by country, vaccine, drug, disease, surveillance method, participant group, and study year. The tool supports vaccine and drug developers, pharmacovigilance programs, and public health stakeholders ... Read more
The objective of the RPP is to leverage investments for advanced-stage clinical development of CEPI's portfolio vaccines and support countries in key regions to generate emergency evidence in future outbreaks Read more
SPEAC’s Special Populations team, in collaboration with Instituto de Efectividad Clínica y Sanitaria (IECS) and Tulane University, has launched an LSR and meta-analysis tool focused on the safety, effectiveness, and immunogenicity of mpox vaccines Read more
CEPI is pleased to announce that two leading scientific organizations, the International Vaccine Institute (IVI) and the Korea Disease Control and Prevention Agency (KDCA), have officially joined the CLN. The network now comprises 20 facilities... Read more
Resources
In collaboration with TGHN, CEPI created this playbook to bring together the many tools, resources and materials generated for pandemic preparedness and response from the COVID-19 pandemic. The first (Regulatory) chapter is now available.
TRANSVAC Academy offers training modules in vaccine R&D including grant management, statistics, cytometry and advanced process development. CEPI funded scholarships are provided to selected applicants from LMICs.
SPEAC is a CEPI and Brighton Collaboration project. SPEAC provides vaccine safety tools, resources, and expertise throughout the vaccine development process to enhance safety and build confidence in vaccines.
Monitoring Vaccine Performance against SARS CoV-2 Variants
The IVAC COVID-19 Vaccine Effectiveness Project (a CEPI- funded global systematic review which also includes neutralization capacity) outputs are publicly available on VIEWhub to assist all policy makers
International Pandemic Preparedness Secretariat
The IPPS serves to join up relevant states, the private sector, and global health institutions in support of the 100 Days Mission, across vaccines, therapeutics, and diagnostics. It performs a global annual progress review related to the 100 DM which feeds into implementation reports.
Vaccine Development
Process Maps
The UK Vaccine R&D Network has developed vaccine development maps to show key stages in human and veterinary vaccines development up to Phase III clinical trials. These process maps and associated case studies provide support in understanding key stages in vaccine development and where bottlenecks could cause delays.
